Evidence map›Paper›PMID 41432890›Full record

ArticleInternal and emergency medicine2026

Time in therapeutic range as predictor of early left-ventricular thrombosis resolution: a retrospective cohort study.

Arianna Pannunzio, Ilaria Maria Palumbo, Marco Paolo Donadini, Davide Santagata, Walter Ageno, Francesco Dragoni, Antonio Chistolini, Cecilia Becattini, Katarzyna Satula, Danilo Menichelli and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Internal and emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Arianna Pannunzio *Department of General Surgery and Surgical Specialty Paride Stefanini, Sapienza University of Rome, Rome, Italy. arianna.pannunzio@uniroma1.it.ORCID 0000-0002-4901-7626
Ilaria Maria Palumbo *Department of General Surgery and Surgical Specialty Paride Stefanini, Sapienza University of Rome, Rome, Italy.
Marco Paolo DonadiniDepartment of Medicine and Surgery, University of Insubria, Varese, Italy.
Davide SantagataDepartment of Medicine and Surgery, University of Insubria, Varese, Italy.
Walter AgenoDepartment of Medicine and Surgery, University of Insubria, Varese, Italy.
Francesco DragoniHematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Antonio ChistoliniHematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Cecilia BecattiniInternal Vascular and Emergency Medicine-Stroke Unit, University of Perugia, Perugia, Italy.
Katarzyna SatulaInternal Vascular and Emergency Medicine-Stroke Unit, University of Perugia, Perugia, Italy.
Danilo MenichelliDepartment of General Surgery and Surgical Specialty Paride Stefanini, Sapienza University of Rome, Rome, Italy.
Daniele PastoriDepartment of General Surgery and Surgical Specialty Paride Stefanini, Sapienza University of Rome, Rome, Italy.
Pasquale Pignatelli *Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
Emanuele Valeriani *Department of General Surgery and Surgical Specialty Paride Stefanini, Sapienza University of Rome, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vitamin K antagonists (VKAs) for 3-6 months are the recommended treatment for left-ventricular thrombosis (LVT) to achieve thrombus resolution and reduce the risk of cardioembolic events. The aim of this study was to evaluate the association between quality of VKAs and early-6 months-thrombus resolution in patients with LVT. In this retrospective study, patients with LVT referred to three Italian Anticoagulation Clinics between January 2011 and December 2023 were enrolled if they received VKAs and data on LVT resolution up to 6 months of treatment were available. Primary outcome was the effect of time-in-therapeutic range and of INR variability defined according to validated formulas on early thrombus resolution. Fifty-four patients were included. Median age was 68 years and 87% were male. Overall, 41.7% and 35.4% patients had a reduced or moderately reduced left-ventricle ejection fraction and apical aneurysm. Twenty-three patients (42.6%) had early thrombus resolution. For the prediction of early LVT resolution, the best value of TTR was 56% (sensitivity, 57%; specificity, 71%; AUC, 0.657), that of INR variability, formula A was 1.65 (sensitivity, 0%; specificity, 96%; AUC, 0.478) and that of formula B 0.40 (sensitivity, 4%; specificity, 100%; AUC, 0.599). The cumulative incidence of early LVT resolution was higher in patients with TTR values ≥ 56% (57.1%; 95% confidence interval-CI 32.8-75.5%) than < 56% (30.3%; 95% CI 15.6-46.4%).The quality of VKAs anticoagulation may be a relevant driver for early LVT resolution. TTR evaluation appears to have a slightly greater accuracy compared to INR variability.

Indexed as

Heart VentriclesThrombosisAgedAnticoagulantsCohort StudiesFemaleHumansInternational Normalized RatioItalyMaleMiddle AgedRetrospective StudiesTime FactorsVitamin KAnticoagulantsVitamin KAcenocoumarolAnticoagulantsInternational normalized ratioThrombosisWarfarin

Identifiers

PMID41432890

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.